{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:16:48Z","timestamp":1783336608424,"version":"3.54.6"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1038\/s41431-022-01075-0","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T02:02:29Z","timestamp":1646791349000},"page":"507-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The 2019 and 2021 International Workshops on Alport Syndrome"],"prefix":"10.1038","volume":"30","author":[{"given":"Sergio","family":"Daga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5549-9169","authenticated-orcid":false,"given":"Constantinos","family":"Deltas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Savige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4169-9685","authenticated-orcid":false,"given":"Beata S.","family":"Lipska-Zi\u0119tkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-7129","authenticated-orcid":false,"given":"Julia","family":"Hoefele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Flinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3699-1884","authenticated-orcid":false,"given":"Marina","family":"Aksenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Perin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moumita","family":"Barua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Torra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1510-8714","authenticated-orcid":false,"given":"Jeff H.","family":"Miner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Massella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danica Gale\u0161i\u0107","family":"Ljubanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6400-0227","authenticated-orcid":false,"given":"Rachel","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e8 B.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Knebelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne","family":"Cerkauskaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Gear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-873X","authenticated-orcid":false,"given":"A. Neil","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Baldassarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6259-6901","authenticated-orcid":false,"given":"Anna Maria","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-9220","authenticated-orcid":false,"given":"Alessandra","family":"Renieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"1075_CR1","doi-asserted-by":"publisher","unstructured":"Hertz JM, Thomassen M, Storey H, Flinter F. Clinical utility gene card for: Alport syndrome. Eur J Hum Genet. 2015;23. https:\/\/doi.org\/10.1038\/ejhg.2014.254.","DOI":"10.1038\/ejhg.2014.254"},{"key":"1075_CR2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1681\/ASN.2008101086","volume":"20","author":"DR Abrahamson","year":"2009","unstructured":"Abrahamson DR, Hudson BG, Stroganova L, Borza DB, St John PL. Cellular origins of Type IV Collagen Networks in developing Glomeruli. J Am Soc Nephrol. 2009;20:1471\u20139. https:\/\/doi.org\/10.1681\/ASN.2008101086.","journal-title":"J Am Soc Nephrol"},{"key":"1075_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/jmg.29.5.352","volume":"29","author":"F Flinter","year":"1992","unstructured":"Flinter F, Bobrow M. The molecular genetics of Alport syndrome: report of two workshops. J Med Genet. 1992;29:352\u20133. https:\/\/doi.org\/10.1136\/jmg.29.5.352.","journal-title":"J Med Genet"},{"key":"1075_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000435789","volume":"130","author":"C Deltas","year":"2015","unstructured":"Deltas C, Savva I, Voskarides K, Papazachariou L, Pierides A. Carriers of autosomal recessive Alport Syndrome with thin basement membrane nephropathy presenting as focal segmental glomerulosclerosis in later life. Nephron. 2015;130:271\u201380. https:\/\/doi.org\/10.1159\/000435789.","journal-title":"Nephron"},{"key":"1075_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/jmedgenet-2014-102822","volume":"52","author":"MA Mencarelli","year":"2015","unstructured":"Mencarelli MA, Heidet L, Storey H, van Geel M, Knebelmann B, Fallerini C, et al. Evidence of digenic inheritance in Alport syndrome. J Med Genet. 2015;52:163\u201374. https:\/\/doi.org\/10.1136\/jmedgenet-2014-102822.","journal-title":"J Med Genet"},{"key":"1075_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/cge.12919","volume":"92","author":"C Fallerini","year":"2017","unstructured":"Fallerini C, Baldassarri M, Trevisson E, Morbidoni V, La Manna A, Lazzarin R, et al. Alport syndrome: impact of digenic inheritance in patients management. Clin Genet. 2017;92:34\u201344. https:\/\/doi.org\/10.1111\/cge.12919.","journal-title":"Clin Genet"},{"key":"1075_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s10157-016-1352-y","volume":"21","author":"K Yokota","year":"2017","unstructured":"Yokota K, Nozu K, Minamikawa S, Yamamura T, Nakanishi K, Kaneda H, et al. Female X-linked Alport syndrome with somatic mosaicism. Clin Exp Nephrol. 2017;21:877\u201383. https:\/\/doi.org\/10.1007\/s10157-016-1352-y.","journal-title":"Clin Exp Nephrol"},{"key":"1075_CR8","doi-asserted-by":"publisher","first-page":"580376","DOI":"10.3389\/fmed.2020.580376","volume":"7","author":"A Mastrangelo","year":"2020","unstructured":"Mastrangelo A, Giani M, Groppali E, Castorina P, Sold\u00e0 G, Robusto M, et al. X-Linked Alport Syndrome in women: genotype and clinical course in 24 cases. Front Med. 2020;7:580376. https:\/\/doi.org\/10.3389\/fmed.2020.580376.","journal-title":"Front Med"},{"key":"1075_CR9","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/genes11111377","volume":"11","author":"A Zupan","year":"2020","unstructured":"Zupan A, Matja\u0161i\u010d A, Grubelnik G, Tasi\u0107 V, Momirovska A. Mutations in collagen genes in the context of an isolated population. Genes. 2020;11:1377. https:\/\/doi.org\/10.3390\/genes11111377.","journal-title":"Genes"},{"key":"1075_CR10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1053\/j.ajkd.2021.02.326","volume":"78","author":"M Furlano","year":"2021","unstructured":"Furlano M, Mart\u00ednez V, Pybus M, Arce Y, Cresp\u00ed J, Venegas MDP, et al. Clinical and genetic features of autosomal dominant Alport syndrome: a cohort study. Am J Kidney Dis. 2021;78:560\u2013.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2021.02.326.","journal-title":"Am J Kidney Dis"},{"key":"1075_CR11","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1002\/mgg3.653","volume":"7","author":"X Zhao","year":"2019","unstructured":"Zhao X, Chen C, Wei Y, Zhao G, Liu L, Wang C, et al. Novel mutations of COL4A3, COL4A4, and COL4A5 genes in Chinese patients with Alport Syndrome using next generation sequence technique. Mol Genet Genom Med. 2019;7:e653. https:\/\/doi.org\/10.1002\/mgg3.653.","journal-title":"Mol Genet Genom Med"},{"key":"1075_CR12","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/ckj\/sfz176","volume":"13","author":"APT Matthaiou","year":"2020","unstructured":"Matthaiou APT, Deltas C. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review. Clin Kidney J. 2020;13:1025\u201336. https:\/\/doi.org\/10.1093\/ckj\/sfz176.","journal-title":"Clin Kidney J"},{"key":"1075_CR13","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41431-021-00858-1","volume":"29","author":"J Savige","year":"2021","unstructured":"Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, et al. Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet. 2021;29:1186\u201397. https:\/\/doi.org\/10.1038\/s41431-021-00858-1.","journal-title":"Eur J Hum Genet"},{"key":"1075_CR14","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.kint.2020.06.038","volume":"98","author":"T Yamamura","year":"2020","unstructured":"Yamamura T, Horinouchi T, Nagano C, Omori T, Sakakibara N, Aoto Y, et al. Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome. Kidney Int. 2020;98:1605\u201314. https:\/\/doi.org\/10.1016\/j.kint.2020.06.038.","journal-title":"Kidney Int."},{"key":"1075_CR15","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1681\/ASN.2007040444","volume":"18","author":"K Voskarides","year":"2007","unstructured":"Voskarides K, Damianou L, Neocleous V, Zouvani I, Christodoulidou S, Hadjiconstantinou V, et al. COL4A3\/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol. 2007;18:3004\u201316. https:\/\/doi.org\/10.1681\/ASN.2007040444.","journal-title":"J Am Soc Nephrol"},{"key":"1075_CR16","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.ekir.2020.04.011","volume":"5","author":"Y Li","year":"2020","unstructured":"Li Y, Groopman EE, D\u2019Agati V, Prakash S, Zhang J, Mizerska-Wasiak M, et al. Type IV collagen mutations in familial IgA nephropathy. Kidney Int Rep. 2020;5:1075\u20138. https:\/\/doi.org\/10.1016\/j.ekir.2020.04.011.","journal-title":"Kidney Int Rep"},{"key":"1075_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ekir.2019.09.004","volume":"5","author":"A Gulati","year":"2019","unstructured":"Gulati A, Sevillano AM, Praga M, Gutierrez E, Alba I, Dahl NK, et al. Collagen IV gene mutations in adults with bilateral renal cysts and CKD. Kidney Int Rep. 2019;5:103\u20138. https:\/\/doi.org\/10.1016\/j.ekir.2019.09.004.","journal-title":"Kidney Int Rep"},{"key":"1075_CR18","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1093\/ndt\/gfp158","volume":"24","author":"A Pierides","year":"2009","unstructured":"Pierides A, Voskarides K, Athanasiou Y, Ioannou K, Damianou L, Arsali M, et al. Clinico-pathological correlations in 127 patients in 11 large pedigrees, segregating one of three heterozygous mutations in the COL4A3\/ COL4A4 genes associated with familial haematuria and significant late progression to proteinuria and chronic kidney disease from focal segmental glomerulosclerosis. Nephrol Dial Transpl. 2009;24:2721\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfp158.","journal-title":"Nephrol Dial Transpl"},{"key":"1075_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1806891","volume":"380","author":"EE Groopman","year":"2019","unstructured":"Groopman EE, Marasa M, Cameron-Christie S, Petrovski S, Aggarwal VS, Milo- Rasouly H, et al. Diagnostic utility of exome sequencing for kidney disease. N Engl J Med. 2019;380:142\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1806891.","journal-title":"N Engl J Med"},{"key":"1075_CR20","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1681\/ASN.2020071065","volume":"32","author":"J Gibson","year":"2021","unstructured":"Gibson J, Fieldhouse R, Chan MMY, Sadeghi-Alavijeh O, Burnett L, Izzi V, et al. Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome. J Am Soc Nephrol. 2021;32:2273\u201390. https:\/\/doi.org\/10.1681\/ASN.2020071065.","journal-title":"J Am Soc Nephrol"},{"key":"1075_CR21","doi-asserted-by":"publisher","first-page":"e0161802","DOI":"10.1371\/journal.pone.0161802","volume":"11","author":"J Savige","year":"2016","unstructured":"Savige J, Storey H, Il Cheong H, Gyung Kang H, Park E, Hilbert P, et al. X-linked and autosomal recessive Alport syndrome: pathogenic variant features and further genotype-phenotype correlations. PLoS ONE. 2016;11:e0161802. https:\/\/doi.org\/10.1371\/journal.pone.0161802.","journal-title":"PLoS ONE"},{"key":"1075_CR22","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.kint.2020.10.040","volume":"99","author":"AM Zurowska","year":"2021","unstructured":"Zurowska AM, Bielska O, Daca-Roszak P, Jankowski M, Szczepanska M, Roszkowska-Bjanid D, et al. Mild X-linked Alport syndrome due to the COL4A5 G624D variant originating in the middle ages is predominant in Central\/East Europe and causes kidney failure in midlife. Kidney Int. 2021;99:1451\u20138. https:\/\/doi.org\/10.1016\/j.kint.2020.10.040.","journal-title":"Kidney Int"},{"key":"1075_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3389\/fped.2019.00485","volume":"7","author":"EP Macheroux","year":"2019","unstructured":"Macheroux EP, Braunisch MC, Pucci Pegler S, Satanovskij R, Riedhammer KM, G\u00fcnthner R, et al. The Hypomorphic Variant p.(Gly624Asp) in COL4A5 as a possible cause for an unexpected severe phenotype in a family with X-linked Alport syndrome. Front Pediatr. 2019;7:485. https:\/\/doi.org\/10.3389\/fped.2019.00485.","journal-title":"Front Pediatr"},{"key":"1075_CR24","doi-asserted-by":"publisher","unstructured":"Boeckhaus J, Hoefele J, Riedhammer KM, Nagel M, Beck B, Choi M, et al. Lifelong effect of therapy in young patients with the COL4A5 Alport Missense Variant p.(Gly624Asp): a prospective cohort study. Nephrol Dial Transplant. 2022:gfac006. https:\/\/doi.org\/10.1093\/ndt\/gfac006.","DOI":"10.1093\/ndt\/gfac006"},{"key":"1075_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/cge.13861","volume":"99","author":"J Boeckhaus","year":"2021","unstructured":"Boeckhaus J, Hoefele J, Riedhammer KM, T\u00f6nshoff B, Ehren R, Pape L, et al. Precise variant interpretation, phenotype ascertainment, and genotype-phenotype correlation of children in the EARLY PRO-TECT Alport trial. Clin Genet. 2021;99:143\u201356. https:\/\/doi.org\/10.1111\/cge.13861.","journal-title":"Clin Genet"},{"key":"1075_CR26","doi-asserted-by":"publisher","unstructured":"Kasthan CE, Gross O. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. Pediatr Nephrol. 2020. https:\/\/doi.org\/10.1007\/s00467-020-04819-6.","DOI":"10.1007\/s00467-020-04819-6"},{"key":"1075_CR27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00467-011-2084-6","volume":"27","author":"K Voskarides","year":"2012","unstructured":"Voskarides K, Arsali M, Athanasiou Y, Elia A, Pierides A, Delta C. Evidence that NPHS2-R229Q predisposes to proteinuria and renal failure in familial hematuria. Pediatr Nephrol. 2012;27:675\u20139. https:\/\/doi.org\/10.1007\/s00467-011-2084-6.","journal-title":"Pediatr Nephrol"},{"key":"1075_CR28","doi-asserted-by":"publisher","first-page":"e0174274","DOI":"10.1371\/journal.pone.0174274","volume":"12","author":"K Voskarides","year":"2017","unstructured":"Voskarides K, Stefanou C, Pieri M, Demosthenous P, Felekkis K, Arsali M, et al. A functional variant in NEPH3 gene confers high risk of renal failure in primary hematuric glomerulopathies. Evidence for predisposition to microalbuminuria in the general population. PLoS ONE. 2017;12:e0174274. https:\/\/doi.org\/10.1371\/journal.pone.0174274.","journal-title":"PLoS ONE"},{"key":"1075_CR29","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00467-015-3067-9","volume":"30","author":"R Lennon","year":"2015","unstructured":"Lennon R, Stuart HM, Bierzynska A, Randles MJ, Kerr B, Hillman KA, et al. Coinheritance of COL4A5 and MYO1E mutations accentuate the severity of kidney disease. Pediatr Nephrol. 2015;30:1459\u201365. https:\/\/doi.org\/10.1007\/s00467-015-3067-9.","journal-title":"Pediatr Nephrol"},{"key":"1075_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12882-018-0906-5","volume":"19","author":"K Voskarides","year":"2018","unstructured":"Voskarides K, Papagregoriou G, Hadjipanagi D, Petrou I, Savva I, Elia A, et al. COL4A5 and LAMA5 variants co-inherited in familial hematuria: digenic inheritance or genetic modifier effect? BMC Nephrol. 2018;19:114. https:\/\/doi.org\/10.1186\/s12882-018-0906-5.","journal-title":"BMC Nephrol"},{"key":"1075_CR31","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1097\/01.asn.0000090034.71205.74","volume":"14","author":"JP Jais","year":"2003","unstructured":"Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a \u201cEuropean Community Alport Syndrome Concerted Action\u201d study. J Am Soc Nephrol. 2003;14:2603\u201310. https:\/\/doi.org\/10.1097\/01.asn.0000090034.71205.74.","journal-title":"J Am Soc Nephrol"},{"key":"1075_CR32","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41431-021-00858-1","volume":"29","author":"J Savige","year":"2021","unstructured":"Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, et al. Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet. 2021;29:1186\u201397. https:\/\/doi.org\/10.1038\/s41431-021-00858-1.","journal-title":"Eur J Hum Genet"},{"key":"1075_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97414-0","volume":"11","author":"X Wang","year":"2021","unstructured":"Wang X, Zhang Y, Ding J, Wang F. mRNA analysis identifies deep intronic variants causing Alport syndrome and overcomes the problem of negative results of exome sequencing. Sci Rep. 2021;11:18097. https:\/\/doi.org\/10.1038\/s41598-021-97414-0.","journal-title":"Sci Rep."},{"key":"1075_CR34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2215\/CJN.08750718","volume":"14","author":"T Yao","year":"2019","unstructured":"Yao T, Udwan K, John R, Rana A, Haghighi A, Xu L, et al. Integration of genetic testing and pathology for the diagnosis of adults with FSGS. Clin J Am Soc Nephrol. 2019;14:213\u201323. https:\/\/doi.org\/10.2215\/CJN.08750718.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1075_CR35","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ng.3118","volume":"46","author":"K Kiryluk","year":"2014","unstructured":"Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46:1187\u201396. https:\/\/doi.org\/10.1038\/ng.3118.","journal-title":"Nat Genet"},{"key":"1075_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-021-00543-5","volume":"26","author":"Y Ding","year":"2021","unstructured":"Ding Y, Tang X, Du Y, Chen H, Yu D, Zhu B, et al. Co-existence of Alport syndrome and C3 glomerulonephritis in a proband with family history. Eur J Med Res. 2021;26:71. https:\/\/doi.org\/10.1186\/s40001-021-00543-5.","journal-title":"Eur J Med Res"},{"key":"1075_CR37","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.ekir.2021.02.022","volume":"6","author":"A Cambier","year":"2021","unstructured":"Cambier A, Robert T, Hogan J, Rabant M, Peuchmaur M, Boyer O, et al. Rare collagenous heterozygote variants in children with IgA nephropathy. Kidney Int Rep. 2021;6:1326\u201335. https:\/\/doi.org\/10.1016\/j.ekir.2021.02.022.","journal-title":"Kidney Int Rep"},{"key":"1075_CR38","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2021.04.017","volume":"78","author":"J Savige","year":"2021","unstructured":"Savige J, Harraka P. Pathogenic variants in the genes affected in Alport syndrome (COL4A3-COL4A5) and their association with other kidney conditions: a review. Am J Kidney Dis. 2021;78:857\u201364. https:\/\/doi.org\/10.1053\/j.ajkd.2021.04.017.","journal-title":"Am J Kidney Dis"},{"key":"1075_CR39","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.chembiol.2018.02.003","volume":"25","author":"K Omachi","year":"2018","unstructured":"Omachi K, Kamura M, Teramoto K, Kojima H, Yokota T, Kaseda S, et al. A split-luciferase-based trimer formation assay as a high-throughput screening platform for therapeutics in Alport syndrome. Cell Chem Biol. 2018;25:634\u2013643.e4. https:\/\/doi.org\/10.1016\/j.chembiol.2018.02.003.","journal-title":"Cell Chem Biol"},{"key":"1075_CR40","first-page":"9086","volume":"13","author":"L Sun","year":"2021","unstructured":"Sun L, Hao S, Kuang XY, Wu Y, Huang WY. Determination of the pathogenicity of a novel COL4A5 missense variant by CRISPR-Cas9 in kidney podocytes. Am J Transl Res. 2021;13:9086\u201394.","journal-title":"Am J Transl Res"},{"key":"1075_CR41","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","volume":"97","author":"O Gross","year":"2020","unstructured":"Gross O, T\u00f6nshoff B, Weber LT, Pape L, Latta K, Fehrenbach H, et al. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport\u2019s syndrome. Kidney Int. 2020;97:1275\u201386. https:\/\/doi.org\/10.1016\/j.kint.2019.12.015.","journal-title":"Kidney Int"},{"key":"1075_CR42","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/ndt\/gft434","volume":"29","author":"D Rubel","year":"2014","unstructured":"Rubel D, Stock J, Ciner A, Hiller H, Girgert R, M\u00fcller GA, et al. Antifibrotic, nephroprotective effects of Paricalcitol vs. Calcitriol on top of ACE-inhibitor therapy in the COL4A3-knockout mouse-model for progressive renal fibrosis. Nephrol Dial Transpl. 2014;29:1012\u20139. https:\/\/doi.org\/10.1093\/ndt\/gft434.","journal-title":"Nephrol Dial Transpl"},{"key":"1075_CR43","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/ndt\/gfl810","volume":"22","author":"M-L Koepke","year":"2007","unstructured":"Koepke M-L, Weber M, Schulze-Lohoff E, Beirowski B, Segerer S, Gross O. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrol Dial Transpl. 2007;22:1062\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfl810.","journal-title":"Nephrol Dial Transpl"},{"key":"1075_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00467-012-2138-4","volume":"28","author":"CE Kashtan","year":"2013","unstructured":"Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, et al. Clinical practice guidelines for the treatment of Alport syndrome. a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol. 2013;28:5\u201311. https:\/\/doi.org\/10.1007\/s00467-012-2138-4.","journal-title":"Pediatr Nephrol"},{"key":"1075_CR45","doi-asserted-by":"publisher","unstructured":"Gross O, Perin L, Deltas C. Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS-blockade and the horizon of future therapies. Nephrol Dial Transplant. 2014;29:iv124-30. https:\/\/doi.org\/10.1093\/ndt\/gfu028.","DOI":"10.1093\/ndt\/gfu028"},{"key":"1075_CR46","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000513777","volume":"52","author":"GM Chertow","year":"2021","unstructured":"Chertow GM, Appel GB, Andreoli S, Bangalore S, Block GA, Chapman AB, et al. Study design and baseline characteristics of the CARDINAL trial: a phase 3 study of bardoxolone methyl in patients with Alport syndrome. Am J Nephrol. 2021;52:180\u20139. https:\/\/doi.org\/10.1159\/000513777.","journal-title":"Am J Nephrol"},{"key":"1075_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.kint.2020.07.036","volume":"99","author":"BM Rush","year":"2021","unstructured":"Rush BM, Bondi CD, Stocker SD, Barry KM, Small SA, Ong J, et al. Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice. Kidney Int. 2021;99:102\u201316. https:\/\/doi.org\/10.1016\/j.kint.2020.07.036.","journal-title":"Kidney Int"},{"key":"1075_CR48","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"key":"1075_CR49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1515920.","journal-title":"N Engl J Med"},{"key":"1075_CR50","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3390\/cells10071815","volume":"10","author":"J Boeckhaus","year":"2021","unstructured":"Boeckhaus J, Gross O. Sodium-glucose cotransporter-2 inhibitors in patients with hereditary podocytopathies, Alport syndrome, and FSGS: a case series to better plan a large-scale study. Cells. 2021;10:1815. https:\/\/doi.org\/10.3390\/cells10071815.","journal-title":"Cells"},{"key":"1075_CR51","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"key":"1075_CR52","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.3390\/jcm10132958","volume":"10","author":"D Rubel","year":"2021","unstructured":"Rubel D, Zhang Y, Sowa N, Girgert R, Gross O. Organoprotective effects of spironolactone on top of ramipril therapy in a mouse model for the type IV collagen disease Alport syndrome. J Clin Med. 2021;10:2958. https:\/\/doi.org\/10.3390\/jcm10132958.","journal-title":"J Clin Med"},{"key":"1075_CR53","doi-asserted-by":"publisher","unstructured":"Kaseda S, Sannomiya Y, Horizono J, Kuwazuru J, Suico MA, Ogi S, et al. Novel Keap1-Nrf2 Protein-protein interaction inhibitor UBE-1099 ameliorates progressive phenotype in Alport syndrome mouse model. Kidney 360. 2021. https:\/\/doi.org\/10.34067\/KID.0004572021.","DOI":"10.34067\/KID.0004572021"},{"key":"1075_CR54","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385:493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454.","journal-title":"N Engl J Med"},{"key":"1075_CR55","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/humu.23364","volume":"39","author":"S Daga","year":"2018","unstructured":"Daga S, Baldassarri M, Lo Rizzo C, Fallerini C, Imperatore V, Longo I, et al. Urine- derived podocytes-lineage cells: a promising tool for precision medicine in Alport Syndrome. Hum Mutat. 2018;39:302\u201314. https:\/\/doi.org\/10.1002\/humu.23364.","journal-title":"Hum Mutat"},{"key":"1075_CR56","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41431-019-0537-8","volume":"28","author":"S Daga","year":"2020","unstructured":"Daga S, Donati F, Capitani K, Croci S, Tita R, Giliberti A, et al. New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells. Eur J Hum Genet. 2020;28:480\u201390. https:\/\/doi.org\/10.1038\/s41431-019-0537-8.","journal-title":"Eur J Hum Genet"},{"key":"1075_CR57","doi-asserted-by":"publisher","unstructured":"Omachi K, Miner JF. Comparative analysis and rational design of dCas9-VP64 variants for CRISPR activation. bioRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.08.13.456279.","DOI":"10.1101\/2021.08.13.456279"},{"key":"1075_CR58","unstructured":"Feldman DL, Vachon G, Kasthan KE, Rheault M, Simon J, Parziale G, et al. The voice of the patient. Externally led patient-focused Drug Development Meeting on Alport Syndrome. National Kidney Foundation; 2019."}],"updated-by":[{"DOI":"10.1038\/s41431-023-01286-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000}}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01075-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01075-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01075-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T07:07:43Z","timestamp":1674544063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01075-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1075"],"URL":"https:\/\/doi.org\/10.1038\/s41431-022-01075-0","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41431-023-01286-z","asserted-by":"object"}]},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"assertion":[{"value":"19 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update on Acknowledgment.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41431-023-01286-z","URL":"https:\/\/doi.org\/10.1038\/s41431-023-01286-z","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}